Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
Biogen looks beyond aducanumab, and late-stage data loom for Lilly, Bristol Myers Squibb and Novartis.
December promises big US decisions for Novartis, Astrazeneca and Fibrogen, as well as the FDA's first Covid-19 vaccine reviews.
The Covid-19 pandemic might yet delay US approval of Novartis's cholesterol-lowering project Leqvio − and then come the commercial questions.
The FDA will have a busy November, with decisions due for Bristol, Sanofi and Y-mabs, among others.
November 6 is the day that could make or break Biogen.
October brings US approval decisions for Eysuvis and Brilinta, while a panel meeting sets up a discussion around Covid-19 vaccines.
Our final look at upcoming catalysts sees data expected from Replimune, TCR2 Therapeutics, Anavex and more.
Important clinical data are expected in the fourth quarter from biotech companies including Madrigal, Arena, Rhythm and Forma.